Teprotumumab Versus Intravenous Methylprednisolone in Thyroid Eye Disease: A Systematic Review

Overview

Journal Oman J Ophthalmol

Specialty Ophthalmology

Date 2024 Dec 9

PMID 39651498

Authors

Faizan Mehmood

Syed Ali Raza Rizvi

Sarah Alam

Benazir Ansari

Affiliations

Soon will be listed here.

Abstract

Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is an autoimmune disorder caused due to a complex interplay between autoantigens including the thyroid-stimulating hormone receptor and the insulin-like growth factor-I receptor. TED is characterized by progressive proptosis or diplopia. This systematic review aimed to compare the efficacy of the newer monoclonal antibody - teprotumumab and intravenous methylprednisolone (IVMP) in TED patients. We performed a systematic review of previously published studies from 2013 to June 2023. A total of 329 articles were screened; among them, 111 non-duplicate publications were identified. After the screening of titles and abstracts, 156 publications were excluded; then, another 47 published papers were excluded after the full-text screening. The remaining 15 eligible studies were included in this systematic review. The majority of studies used either teprotumumab alone or in combination with others. Among 15 studies, eight studies used teprotumumab in TED patients, whereas remaining 7 studies used a standard treatment regimen. This systematic review provides an overview of the existing treatment options using monoclonal antibody - teprotumumab and IVMP in TED patients. The overall assessment provides a finding that antibody - teprotumumab is is a good choice compared to conventional IVMP for providing better outcomes in patients with TED.

References

Zang S, Ponto K, Kahaly G . Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96(2):320-32. DOI: 10.1210/jc.2010-1962. View

Jang J, Park J, Park K, Kim Y, Woo K . Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2023; 261(8):2375-2382. DOI: 10.1007/s00417-023-06013-4. View

Girnita L, Smith T, Janssen J . It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022; 107(Suppl_1):S1-S12. PMC: 9359450. DOI: 10.1210/clinem/dgac045. View

Jongen P, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen W . Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016; 263(8):1641-51. PMC: 4971042. DOI: 10.1007/s00415-016-8183-3. View

Neumann S, Krieger C, Gershengorn M . Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease. Eur Thyroid J. 2021; 9(Suppl 1):59-65. PMC: 7802449. DOI: 10.1159/000511538. View

He Y, Mu K, Liu R, Zhang J, Xiang N . Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial. Endocr J. 2016; 64(2):141-149. DOI: 10.1507/endocrj.EJ16-0083. View

Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

Krieger C, Boutin A, Jang D, Morgan S, Banga J, Kahaly G . Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk. Endocrinology. 2019; 160(6):1468-1479. PMC: 6542485. DOI: 10.1210/en.2019-00055. View

Stevens S, Pirakitikulr N, Lee B . Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan J Ophthalmol. 2022; 12(1):39-43. PMC: 8988969. DOI: 10.4103/tjo.tjo_59_21. View

10.

Mayer E, Fox D, Herdman G, Hsuan J, Kabala J, Goddard P . Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005; 56(1):20-4. DOI: 10.1016/j.ejrad.2005.03.027. View

11.

Kossler A, Douglas R, Dosiou C . Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022; 107(Suppl_1):S36-S46. PMC: 9359446. DOI: 10.1210/clinem/dgac168. View

12.

Lai K, Aljufairi F, Li C, Ngai A, Yeung C, Fong R . Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy. J Clin Med. 2023; 12(9). PMC: 10179467. DOI: 10.3390/jcm12093244. View

13.

Strianese D, Rossi F . Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy. Eye (Lond). 2019; 33(2):191-199. PMC: 6367473. DOI: 10.1038/s41433-018-0315-9. View

14.

Kahaly G, Pitz S, Hommel G, Dittmar M . Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005; 90(9):5234-40. DOI: 10.1210/jc.2005-0148. View

15.

Rao R, MacIntosh P, Yoon M, Lefebvre D . Current trends in the management of thyroid eye disease. Curr Opin Ophthalmol. 2015; 26(6):484-90. DOI: 10.1097/ICU.0000000000000203. View

16.

Ugradar S, Goldberg R, Rootman D . Bony Orbital Volume Expansion in Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018; 35(5):434-437. DOI: 10.1097/IOP.0000000000001292. View

17.

Pritchard J, Han R, Horst N, Cruikshank W, Smith T . Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003; 170(12):6348-54. DOI: 10.4049/jimmunol.170.12.6348. View

18.

Marcocci C, Kahaly G, Krassas G, Bartalena L, Prummel M, Stahl M . Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011; 364(20):1920-31. DOI: 10.1056/NEJMoa1012985. View

19.

Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R . Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18):1748-1761. PMC: 5718164. DOI: 10.1056/NEJMoa1614949. View

20.

Teo H, Smith T, Joseph S . Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Ther Clin Risk Manag. 2021; 17:1219-1230. PMC: 8630371. DOI: 10.2147/TCRM.S303057. View